ObvioGo Now Integrated with Oracle Life Sciences Clinical One Data Collection

New collaboration expands access to decentralized trial capabilities within Oracle's enterprise-grade clinical R&D portfolio.

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

ObvioHealth and Oracle Health and Life Sciences have announced that ObvioGo®, ObvioHealth's enterprise-grade ePRO, eConsent, and eCOA platform, is now directly integrated with Oracle Health and Life Sciences Clinical One Data Collection. This integration enables sponsors and CROs to deploy participant-facing trial technologies configured and delivered through ObvioGo as part of a comprehensive, unified clinical trial system within Oracle's product portfolio.

Why it matters

The collaboration between ObvioHealth and Oracle Health and Life Sciences aims to help life sciences organizations modernize clinical development by providing access to decentralized trial capabilities that integrate seamlessly within Oracle's enterprise-grade solutions. This integration supports efficient trial execution, data quality, operational oversight, and regulatory compliance for decentralized and hybrid study designs.

The details

The integrated offering extends Oracle Health and Life Sciences Clinical R&D portfolio with ObvioGo's participant-facing trial technologies. This direct integration enables sponsors and CROs to deploy ObvioGo's ePRO, eConsent, and eCOA capabilities as part of a comprehensive, unified clinical trial system within Oracle's product suite. By bringing these capabilities together, organizations can limit reliance on multiple third-party solutions while maintaining consistency, oversight, and scalability across global studies.

  • The integration was announced on February 10, 2026.

The players

ObvioHealth

A digital technology company that provides solutions to support the execution of decentralized, hybrid, and traditional clinical trials across therapeutic areas.

Oracle Health and Life Sciences

A division of Oracle Corporation that focuses on delivering connected, enterprise-grade solutions to help life sciences organizations modernize clinical development.

ObvioGo

ObvioHealth's enterprise-grade platform that enables ePRO, eConsent, and eCOA capabilities for clinical trials.

Oracle Health and Life Sciences Clinical One Data Collection

Oracle's clinical R&D portfolio that provides a comprehensive, unified clinical trial system.

Seema Verma

Executive vice president and general manager of Oracle Health and Life Sciences.

Richard Watkins

Chief revenue officer of ObvioHealth.

Ivan Jarry

CEO of ObvioHealth.

Got photos? Submit your photos here. ›

What they’re saying

“Oracle Health and Life Sciences is focused on delivering connected, enterprise-grade solutions that help sponsors modernize clinical development. With ObvioGo, we are expanding access to decentralized trial capabilities that integrate seamlessly within Oracle Health and Life Sciences product portfolio.”

— Seema Verma, Executive vice president and general manager, Oracle Health and Life Sciences

“This collaboration represents an important milestone for ObvioHealth. Being integrated and sold as part of Oracle Health and Life Sciences validates ObvioGo as an enterprise-ready participant technology platform designed to operate at global scale alongside Oracle Health and Life Sciences.”

— Richard Watkins, Chief revenue officer, ObvioHealth

“Together, ObvioHealth and Oracle Health and Life Sciences are delivering an integrated clinical trial experience that addresses the evolving needs of modern research. This collaboration enables sponsors to simplify trial operations while maintaining the flexibility required to support decentralized and hybrid study designs.”

— Ivan Jarry, CEO, ObvioHealth

What’s next

The integration of ObvioGo with Oracle Health and Life Sciences Clinical One Data Collection is expected to provide life sciences organizations with a comprehensive, unified platform to support decentralized and hybrid clinical trials at scale.

The takeaway

This collaboration between ObvioHealth and Oracle Health and Life Sciences represents a significant step forward in the adoption of decentralized trial technologies, as life sciences organizations can now access enterprise-grade participant-facing solutions that are seamlessly integrated within Oracle's broader clinical R&D portfolio.